Macrophages in Heart Failure with Reduced versus Preserved Ejection Fraction

Matthew DeBerge*, Sanjiv J. Shah, Lisa Wilsbacher, Edward B. Thorp

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

44 Scopus citations


There is a growing number of individuals living with heart failure (HF) with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF). Long-term prognosis remains poor in both cases, especially in HFpEF, which is rising in incidence and lacks effective therapeutics. In both HFrEF and HFpEF, there is evidence that elevated inflammatory biomarkers, implicating innate immune cells such as macrophages, are associated with worsened clinical outcomes. Macrophage subsets are active in both inflammatory and reparative processes, yet our understanding of the causative roles for these cells in HF development and progression is incomplete. Here, we discuss recent findings interrogating the role of macrophages in inflammation and its resolution in the context of HF, with a specific focus on HFrEF versus HFpEF.

Original languageEnglish (US)
Pages (from-to)328-340
Number of pages13
JournalTrends in Molecular Medicine
Issue number4
StatePublished - Apr 2019


  • heart failure
  • inflammation
  • macrophage
  • preserved ejection fraction
  • reduced ejection fraction

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology


Dive into the research topics of 'Macrophages in Heart Failure with Reduced versus Preserved Ejection Fraction'. Together they form a unique fingerprint.

Cite this